Patient characteristics at trial entry
| Baseline characteristics . | N (%) (N = 58) . |
|---|---|
| Age, y | |
| Median (range) | 52 (20-68) |
| Sex | |
| Female | 23 (40%) |
| Male | 35 (60%) |
| Blood group | |
| A | 25 (43%) |
| O | 24 (41%) |
| B | 6 (10%) |
| AB | 3 (5%) |
| Ethnicity | |
| White | 40 (69%) |
| Asian or Asian British | 10 (17%) |
| Mixed race | 4 (7%) |
| Black or Black British | 3 (5%) |
| Chinese | 1 (2%) |
| Performance status | |
| 70% | 2 (3%) |
| 80% | 5 (9%) |
| 90% | 27 (47%) |
| 100% | 24 (41%) |
| Primary diagnosis | |
| Acute myeloid leukemia | 27 (47%) |
| Acute lymphoblastic leukemia | 7 (12%) |
| Non-Hodgkin (follicular lymphoma, B-cell lymphoma) | 7 (12%) |
| Myelodysplasia syndrome | 7 (12%) |
| Other leukemias (chronic myelomonocytic leukemia, T-prolymphocytic leukemia, natural killer cell leukemia) | 3 (5%) |
| Hodgkin lymphoma | 3 (5%) |
| Acute undifferentiated leukemia | 1 (2%) |
| Chronic myeloid leukemia | 1 (2%) |
| Multiple myeloma | 1 (2%) |
| Primary myelofibrosis transformed to acute myeloid leukemia | 1 (2%) |
| Disease status at registration | |
| Complete response | 46 (79%) |
| Partial response | 8 (14%) |
| Progression/relapse | 2 (3%) |
| Accelerated phase | 1 (2%) |
| Unknown | 1 (2%) |
| Comorbidity index | |
| 0 | 28 (48%) |
| 1 | 12 (21%) |
| 2 | 8 (14%) |
| 3+ | 9 (16%) |
| Not reported | 1 (2%) |
| Lines of prior treatment | |
| 0 | 1 (2%) |
| 1 | 17 (29%) |
| 2 | 26 (45%) |
| 3+ | 14 (24%) |
| Baseline characteristics . | N (%) (N = 58) . |
|---|---|
| Age, y | |
| Median (range) | 52 (20-68) |
| Sex | |
| Female | 23 (40%) |
| Male | 35 (60%) |
| Blood group | |
| A | 25 (43%) |
| O | 24 (41%) |
| B | 6 (10%) |
| AB | 3 (5%) |
| Ethnicity | |
| White | 40 (69%) |
| Asian or Asian British | 10 (17%) |
| Mixed race | 4 (7%) |
| Black or Black British | 3 (5%) |
| Chinese | 1 (2%) |
| Performance status | |
| 70% | 2 (3%) |
| 80% | 5 (9%) |
| 90% | 27 (47%) |
| 100% | 24 (41%) |
| Primary diagnosis | |
| Acute myeloid leukemia | 27 (47%) |
| Acute lymphoblastic leukemia | 7 (12%) |
| Non-Hodgkin (follicular lymphoma, B-cell lymphoma) | 7 (12%) |
| Myelodysplasia syndrome | 7 (12%) |
| Other leukemias (chronic myelomonocytic leukemia, T-prolymphocytic leukemia, natural killer cell leukemia) | 3 (5%) |
| Hodgkin lymphoma | 3 (5%) |
| Acute undifferentiated leukemia | 1 (2%) |
| Chronic myeloid leukemia | 1 (2%) |
| Multiple myeloma | 1 (2%) |
| Primary myelofibrosis transformed to acute myeloid leukemia | 1 (2%) |
| Disease status at registration | |
| Complete response | 46 (79%) |
| Partial response | 8 (14%) |
| Progression/relapse | 2 (3%) |
| Accelerated phase | 1 (2%) |
| Unknown | 1 (2%) |
| Comorbidity index | |
| 0 | 28 (48%) |
| 1 | 12 (21%) |
| 2 | 8 (14%) |
| 3+ | 9 (16%) |
| Not reported | 1 (2%) |
| Lines of prior treatment | |
| 0 | 1 (2%) |
| 1 | 17 (29%) |
| 2 | 26 (45%) |
| 3+ | 14 (24%) |